Narcolepsy type 1 is a chronic, rare neurological disease caused by the loss of orexin neurons in the brain. Orexin is a ...

Switching from a higher to a lower-sodium dose of Xywav led to significant reductions in 24-hour blood pressure for ...

A mathematical model reveals circadian rhythms' impact on medication efficacy, particularly for neurological conditions like Parkinson’s disease and depression. The model focuses on dopamine reuptake ...

“I am delighted to serve as guest editor for the recently published CNS Drugs supplement, focused on key clinical issues for people with narcolepsy and their clinicians with a particular emphasis on ...

"Centessa’s stock recovers from drop on sleep drug data" was originally created and published by Clinical Trials Arena, a ...

Alkermes and Takeda Pharmaceuticals said Monday that their respective drug candidates for a form of narcolepsy substantially helped patients stay awake, fueling the race to develop a new class of ...

Some generic Adderall medications are being recalled over potential impurities and mislabled bottles. Here's what to know ...

The "United States Narcolepsy Drugs Market to Reach US$ 2,233.56 Million by 2033 - 7.88% CAGR Driven by Novel Therapies and Better Diagnosis" report has been added to ResearchAndMarkets.com's offering ...

Shares of Harmony Biosciences rose after the pharmaceutical company bumped up its full-year revenue guidance on the strength of its narcolepsy treatment. The stock was recently up 12% at $29.43, on ...